Telix Pharm Ltd (TLPPF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and good evening everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telex and it's my pleasure to welcome you today to our H1 2026 interim results presentation and call. You'll have seen our documents lodged on the ASX earlier this morning. Next slide please. Today on our call we'll be joined by Dr. Christian Behrenbruch, Managing Director and Group CEO, Darren Smith, our Group Chief Financial Officer, Kevin Richardson, CEO of the Telex Precision Medicine business, and Dr. David Cade, Chief Medical Officer. Following prepared remarks, we will open up the call to Q&A, starting with calls on the conference line. If we don't get to your questions during the call, we'll respond to you after the call is finished. Just move to the next slide, please. Brief notice that please note that today's presentation includes forward-looking statements including within the meaning of the US Private Securities Litigation Reform Act of 1995 that relate to, among other things, anticipated future events, financial performance, plans, strategies and business developments. These forward-looking statements are based on current information, assumption and expectations of future events that are subject to change and involve risks and uncertainties that may cause the actual results to differ materially from those containing forward-looking statements. These and other risks are described in our filings with the ASX and SEC, including our half-year and annual reports. You are cautioned not to rely on these forward-looking statements, which are made only as of today's date, and the company disclaims any obligation to update such statements. Please refer to the disclaimer slide included in the presentation accompanying this webcast for fur...